460 related articles for article (PubMed ID: 23670176)
1. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Tomita A; Kiyoi H; Naoe T
Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
[TBL] [Abstract][Full Text] [Related]
2. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
3. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
4. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
6. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARĪ±.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy.
Fang J; Chen SJ; Tong JH; Wang ZG; Chen GQ; Chen Z
Cancer Biol Ther; 2002; 1(6):614-20. PubMed ID: 12642682
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.
Chen Z; Wang ZY; Chen SJ
Pharmacol Ther; 1997; 76(1-3):141-9. PubMed ID: 9535176
[TBL] [Abstract][Full Text] [Related]
11. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
[TBL] [Abstract][Full Text] [Related]
13. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
14. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Jing Y; Waxman S
Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
16. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
18. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
Shinjo K; Takeshita A; Sahara N; Kobayashi M; Nakamura S; Shigeno K; Naito K; Maekawa M; Ohnishi K; Ohno R
Intern Med; 2005 Aug; 44(8):818-24. PubMed ID: 16157979
[TBL] [Abstract][Full Text] [Related]
19. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
[TBL] [Abstract][Full Text] [Related]
20. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
